3- guanidinocarbonyl- 2- methyl- 6,7,8,9- tetrahydro- 5H- cyclohepta(b)pyridine- 9- ylmethyl sulfuric acid

04/01/2016 - "This study aim was to evaluate the efficacy and safety of TY-51924 in patients with STEMI. "
02/01/2016 - "This open-label, dose-escalating study was undertaken to investigate the safety, efficacy, and pharmacokinetics of TY-51924 in patients with ST-elevation myocardial infarction (STEMI). "
02/01/2016 - "Therefore, TY-51924 is thought to be safe in patients with STEMI, even at the highest dose. "
01/01/2014 - "This is a multicenter, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy and the safety of TY-51924 in patients with first anterior STEMI who are undergoing pPCI. "
01/01/2014 - "The appropriateness of assessing safety and efficacy of TY-51924 as adjunctive therapy to pPCI for patients with STEMI will be discussed in this study plan."

02/01/2016 - "Evaluation of the safety and efficacy of TY-51924 in patients with ST elevated acute myocardial infarction - Early phase II first in patient pilot study."
04/01/2016 - "Randomized controlled trial of TY-51924, a novel hydrophilic NHE inhibitor, in acute myocardial infarction."
01/01/2014 - "Trial design and rationale of TY-51924 as a novel Na+/H+ exchanger inhibitor in patients with ST-elevation acute myocardial infarction undergoing percutaneous coronary intervention."

04/01/2016 - "TY-51924, a novel NHE inhibitor, significantly reduced infarct size in animal studies and was well tolerated in early-phase clinical trials. "
04/01/2014 - "This indicates that maintaining a plasma drug concentration of >20 μg/mL at reperfusion enables TY-51924 to reduce infarct size by inhibiting the NHE, which is activated during the early period of reperfusion."
04/01/2014 - "The infarct size reduction ratios of TY-51924 at 5 and 10 mg/kg versus vehicle were 32.8% and 52.4%, respectively. "
04/01/2014 - "In 2-step intravenous infusion initiated 15 minutes before reperfusion, TY-51924 at low dose (3.8 mg/kg per 5 minutes, then 6.2 mg/kg per 20 minutes) and at high dose (7.6 mg/kg per 5 minutes, then 12.4 mg/kg per 20 minutes) reduced infarct size. "
04/01/2014 - "In anesthetized dogs subjected to 90 minutes ischemia/300 minutes reperfusion, intravenous bolus TY-51924 at 5 and 10 mg/kg administered 5 minutes before reperfusion reduced infarct size. "

04/01/2014 - "The cardioprotective effects of novel Na+/H+ exchanger inhibitor TY-51924 on ischemia/reperfusion injury."

04/01/2014 - "In anesthetized dogs subjected to 90 minutes ischemia/300 minutes reperfusion, intravenous bolus TY-51924 at 5 and 10 mg/kg administered 5 minutes before reperfusion reduced infarct size. "